Injection, Daratumumab, 10 mg (J9145)

Name of the Procedure:

• Common Names: Daratumumab Injection
• Medical Term: Injection, daratumumab, 10 mg (HCPCS Code: J9145)

Summary

This procedure involves the administration of daratumumab, a medication used to treat certain types of multiple myeloma. It is given through an injection, typically in a clinical setting.

Purpose

Medical Conditions Addressed:

• Multiple myeloma

Goals:

• To reduce or eliminate cancerous cells in patients with multiple myeloma.
• To improve patient survival rates and quality of life.

Indications

• Diagnosed multiple myeloma
• Patients who have undergone at least one prior therapy or have specified genetic markers

Preparation

• Fasting may not be required but follow specific instructions provided by the healthcare provider.
• Blood tests and other diagnostic assessments (like kidney function tests) may be needed to ensure the patient is a good candidate for the treatment.

Procedure Description

1. The patient is seated comfortably in a reclining chair.
2. An intravenous (IV) line is established to administer the medication.
3. Pre-medications such as corticosteroids and antihistamines may be provided to minimize allergic reactions.
4. Daratumumab is infused slowly through the IV, typically over several hours.
5. The dosage and rate are carefully monitored by healthcare professionals.

Tools and Technology:

• IV infusion equipment
• Monitoring devices for vital signs

Anesthesia/Sedation:

• Not typically required, but sedatives may be offered if the patient is anxious.

Duration

• The infusion generally takes between 2 to 6 hours, depending on the patient's response and the infusion schedule.

Setting

• Usually performed in a hospital, outpatient clinic, or specialized infusion center.

Personnel

• Oncologists or hematologists
• Registered nurses trained in chemotherapy and biologic infusions
• Support staff and pharmacists

Risks and Complications

Common Risks:

• Infusion-related reactions (fever, chills, rash)
• Fatigue
• Nausea

Rare Complications:

• Severe allergic reactions (anaphylaxis)
• Respiratory issues
• Hypotension

Management:

• Monitoring and prompt intervention by healthcare staff
• Pre-medications to minimize risks

Benefits

• Potential reduction in cancerous cells
• Prolonged remission and improved survival rates
• Enhanced quality of life with managed symptoms

Recovery

• Post-procedure observation for a short period to monitor for adverse reactions
• Patients can generally return to normal activities within a day
• Follow-up appointments to assess effectiveness and manage any side effects

Alternatives

Other Treatment Options:

• Alternative chemotherapy agents
• Stem cell transplantation
• Immunotherapy

Pros and Cons:

• Other treatments may offer different scope and side effects
• Daratumumab is often chosen due to its efficacy and specific action on multiple myeloma cells

Patient Experience

• Patients may feel some discomfort or mild pain at the injection site.
• Possible mild side effects like fatigue or chills.
• Pain management includes over-the-counter pain relievers and prescribed medications if necessary.
• The infusion process is closely monitored to ensure patient comfort and safety.